CLINICAL TRIALS PROFILE FOR AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
✉ Email this page to a colleague
All Clinical Trials for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Yokoyama Foundation for Clinical Pharmacology | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00149084 ↗ | Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori | Unknown status | Hamamatsu University | Phase 3 | 2003-04-01 | The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy. |
| NCT00281047 ↗ | The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy | Unknown status | Oita University | Phase 2/Phase 3 | 2006-01-01 | FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. |
| NCT00281047 ↗ | The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy | Unknown status | Hamamatsu University | Phase 2/Phase 3 | 2006-01-01 | FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Condition Name
Clinical Trial Locations for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Trials by Country
Clinical Trial Progress for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Clinical Trial Phase
Clinical Trial Sponsors for AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE
Sponsor Name
